Yang I. Pachankis

Company snapshot

Yang I. Pachankis is a pharma organization headquartered in CN. Primary therapeutic focus areas include Severe Acute Respiratory Syndrome-related Coronavirus. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: approved (1).

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Yang I. Pachankis. Not investment advice.

• What is Yang I. Pachankis?

  Yang I. Pachankis is a pharma organization headquartered in CN. Primary therapeutic focus areas include Severe Acute Respiratory Syndrome-related Coronavirus. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA

• Is Yang I. Pachankis publicly traded?

  Yang I. Pachankis appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Yang I. Pachankis develop or market?

  We link 2 drug profile(s) where Yang I. Pachankis is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/yang-i-pachankis#company-drugs.

• What are the latest developments for Yang I. Pachankis?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Yang I. Pachankis focus on?

  Yang I. Pachankis focuses on Severe Acute Respiratory Syndrome-related Coronavirus based on our analysis of their pipeline programs and drug development activities.